ESG gap analysis – Liminal Biopharmaceutical
Liminal BioSciences is a biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases of unmet medical need, primarily related to fibrosis, including respiratory, liver and kidney diseases.
Liminal Biosciences is publicly listed on the NASDAQ.
Evolveable Consulting were engaged to perform an ESG gap analysis for Liminal due to increasing regulatory and stakeholder expectations, including increased liabilities from a public listed companies perspective.
This gap analysis process involves several detailed interviews with the executive team and key stakeholders within the company.
A total of 29 gaps and recommendations for action were developed and presented to the Liminal team to mitigate ESG risks over the short-, medium- and long-term time horizons.